So on Arexvy, obviously, you saw a rapid penetration ... as well as critical success with STCO in Germany, in addition to the U.S., I think it's an encouraging start. I think what also is ...

The international consulting firm Clarivate makes its bet among the novelties ready for the medicine cabinet this year: three ...

That largely reflects the uncertainty surrounding the prospects for Pfizer’s RSV vaccine, which is already approved as Arexvy for people ... including the UK, Germany, Italy, Spain, Japan ...

FLENSBURG, Germany — Friedrich Merz is Germany’s likely next chancellor, but how he will form a coalition government is looking increasingly uncertain. At a campaign event on Friday in the northern ...

Vaccines sales declined 3% in 2024, reflecting pressures on Arexvy and Shingrix in the U.S. However, Arexvy remains the market leader, and international uptake is gaining momentum. Emily Field ...

GSK reported a similar state of affairs Wednesday. Sales of its RSV vaccine Arexvy declined 69% year over year due to lower demand “related to a more limited recommendation ... for individuals ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

After a blockbuster burst onto the market last year, sales of the RSV vaccine Arexvy nosedived this season. In a similar pattern already seen in the third quarter, Arexvy sales in the fourth ...

Vaccine sales fell 14% (-11% at constant currency) to 2.21 billion pounds, primarily impacted by lower demand for Arexvy related to a more limited ACIP recommendation in the U.S. and channel ...

Vaccine sales fell 14% to £2.21B, with Arexvy sales down 70%, while Specialty Medicines grew 14% to £3.29B, and HIV drug revenue rose. Brand New Membership Level: Benzinga Trade Alerts Vaccine ...

Meanwhile, vaccine sales slipped by 4% for the year, driven by a sharp drop for its Arexvy lung disease treatment. Operating profits dropped by 40% to £4 billion due to a £1.8 billion settlement ...

U.S. health officials in June narrowed Arexvy's patient recommendation to a smaller age range and more at-risk patients. On the contrary, its specialty-medicines sales are expected to increase by ...